Evaluating the Effectiveness of COVID-19 Vaccines Over Time

Danyu Lin, Ph.D.

Dennis Gillings Distinguished Professor
Department of Biostatistics
University of North Carolina at Chapel Hill
United States

WHO Meeting on COVID-19 Vaccines Research

January 28, 2022
VACCINE EFFICACY/EFFECTIVENESS (VE)

VE on hazard rate over time: 1—time-varying hazard ratio
- instantaneous (current) risk
- need for and optimal timing of booster vaccination
- Cox regression model with time-varying hazard ratio
- continuous piecewise log-linear function of time
- VE curve as a continuous function of time since dose 1

VE under proportional hazards model: 1—constant hazard ratio
- average of time-varying hazard ratio over time period
- non-informative about VE at end of time period
# VACCINE EFFICACY IN CLINICAL TRIALS

**VE Against Symptomatic COVID-19 in Phase 3 Trials**

**Pfizer Vaccine (Thomas et al, NEJM, 2021)**

<table>
<thead>
<tr>
<th>Time since Dose 2</th>
<th>VE (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 days – 2 months</td>
<td>96.2% (93.3%, 98.1%)</td>
</tr>
<tr>
<td>2 months – 4 months</td>
<td>90.1% (86.6%, 92.9%)</td>
</tr>
<tr>
<td>4 months – 6 months</td>
<td>83.7% (74.7%, 89.9%)</td>
</tr>
</tbody>
</table>

**Moderna Vaccine (El Sahly et al., NEJM, 2021)**

<table>
<thead>
<tr>
<th>Time since Dose 2</th>
<th>VE (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14 days – 2 months</td>
<td>94.1% (89.3%, 96.8%)</td>
</tr>
<tr>
<td>14 days – 6 months</td>
<td>93.2% (91.0%, 94.8%)</td>
</tr>
</tbody>
</table>
Figure 2. VE against COVID-19 in phase 3 vaccine trials.
**Figure 3.** VE against COVID-19 in Moderna phase 3 trial.
Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina

Dan-Yu Lin, Ph.D., Yu Gu, B.S., Bradford Wheeler, M.P.H., Hayley Young, M.P.H.,
Shannon Holloway, Ph.D., Shadia-Khan Sunny, M.D., Ph.D., M.P.H.,
Zack Moore, M.D., M.P.H., and Donglin Zeng, Ph.D.

ABSTRACT

BACKGROUND
The duration of protection afforded by coronavirus disease 2019 (Covid-19) vaccines in the United States is unclear. Whether the increase in postvaccination infections during the summer of 2021 was caused by declining immunity over time, the emergence of the B.1.617.2 (delta) variant, or both is unknown.

METHODS
We extracted data regarding Covid-19–related vaccination and outcomes during a 9-month period (December 11, 2020, to September 8, 2021) for approximately 10.6 million North Carolina residents by linking data from the North Carolina Covid-19 Surveillance System and the Covid-19 Vaccine Management System. We used a Cox regression model to estimate the effectiveness of the BNT162b2 (Pfizer–BioNTech), mRNA-1273 (Moderna), and Ad26.COV2.S (Johnson & Johnson–Janssen) vaccines in reducing the current risks of Covid-19, hospitalization, and death, as a function of time elapsed since vaccination.

From the Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill (D.-Y.L., Y.G., D.Z.), and the North Carolina Department of Health and Human Services (B.W., H.Y., Z.M.), North Carolina State University (S.H.), and the CDC Foundation, North Carolina Department of Health and Human Services (S.-K.S.), Raleigh. Dr. Lin can be contacted at lin@bios.unc.edu or at the Department of Biostatistics, University of North Carolina at Chapel Hill, 3101E McGavran-Greenberg Hall, Chapel Hill, NC 27599.

This article was published on January 12, 2022, at NEJM.org.

DOI: 10.1056/NEJMoa2117128
Copyright © 2022 Massachusetts Medical Society.
Figure 4. VE against COVID-19.
Figure 5. VE of Pfizer vaccine against COVID-19 by age group.
Figure 6. VE of Moderna vaccine against COVID-19 by age group.
Figure 7. VE of Janssen vaccine against COVID-19 by age group.

- Red: 18–34 yr
- Blue: 50–64 yr
- Green: 35–49 yr
- Orange: ≥ 65 yr
**Figure 8.** VE of Pfizer against COVID-19 by date of first dose.
Figure 9. VE of Moderna against COVID-19 by date of first dose.
Figure 10. VE of Janssen against COVID-19 by date of first dose.
Figure 11. VE against hospitalization.
Figure 12. VE against death.
ONGOING WORK

Phase 3 Trials
- Blinded follow-up data
- Post-crossover data
- Efficacy of boosters

Surveillance Data
- Effectiveness over one year
- Effectiveness of boosters
- Impact of Omicron variant

Other Collaborations?

Email address: lin@bios.unc.edu
REFERENCES

